(Q34885660)

5 August 2017

1 reference

title

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection (English)

1 reference

5 August 2017

1 reference

ChEBI release 2020-05-28

David E Martin

1

1 reference

5 August 2017

Karl Salzwedel

series ordinal

2

1 reference

5 August 2017

Graham P Allaway

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Antiviral Chemistry & Chemotherapy

5 August 2017

1 reference

5 August 2017

19

1 reference

5 August 2017

3

1 reference

5 August 2017

107-113

1 reference

AIDS: is there an answer to the global pandemic? The immune system in HIV infection and control.

5 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Limitations of current antiretroviral agents and opportunities for development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Approach to the treatment-experienced patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Management of HIV-infected patients with multidrug-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Treatment of antiretroviral-drug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

HIV drug development: the next 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Emerging drug targets for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020801900301

10.1177/095632020801900301

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference